The prothrombotic state in cancer: Pathogenic mechanisms

Critical Reviews in Oncology/Hematology

Volumn 50, Issue 3, 2004, Pages 187-196

  De Cicco, Marcello ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Cancer; Prothrombotic state; Thrombosis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; PLASMINOGEN ACTIVATOR INHIBITOR; TAMOXIFEN; THROMBOCYTE ACTIVATING FACTOR;

ANGIOGENESIS; BLOOD CLOTTING; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL VENOUS CATHETER; COMPRESSION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIUM CELL; FIBRINOLYSIS; HEMODYNAMICS; HORMONAL THERAPY; HUMAN; INFLAMMATION; MACROPHAGE; MOLECULAR RECOGNITION; MONOCYTE; PATHOGENESIS; PATHOGENICITY; PATIENT CARE; PROBABILITY; REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS;

BIOLOGICAL MARKERS; BLOOD CELLS; BLOOD COAGULATION; CYSTEINE ENDOPEPTIDASES; CYTOKINES; DISSEMINATED INTRAVASCULAR COAGULATION; FIBRINOLYSIS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THROMBOPLASTIN; THROMBOSIS;

EID: 2942616892     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2003.10.003     Document Type: Review

References (124)

1. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris. London: The New Sydenham Society. 3:1865;94-99
2. Sack G.H. Jr., Levin J., Bell W.R. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine. 56:1977;1-37
3. Sun N.C., McAfee W.M., Hum G.J., Weiner J.M. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am. J. Clin. Pathol. 71:1979;10-16
4. Bick R.L. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin. Thromb. Hemost. 5:1978;1-26
5. Hemostatic abnormalities and malignant disease. Lancet 1986;1(8476):303-4 [Editorial].
6. Nand S., Fisher S.G., Salgia R., Fisher R.I. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J. Clin. Oncol. 5:1987;1998-2003
7. Weick J.K. Intravascular coagulation in cancer. Semin. Oncol. 5:1978;203-211
8. Goodnight S.H. Jr. Bleeding and intravascular clotting in malignancy: a review. Ann. N.Y. Acad. Sci. 230:1974;271-288
9. Falanga A., Rickles F.R. Pathophysiology of the thrombophilic state in the cancer patient. Semin. Thromb. Hemost. 25:1999;173-182
10. Gouin-Thibault I., Achkar A., Samama M.M. The thrombophilic state in cancer patients. Acta Haematol. 106:2001;33-42
11. Falanga A., Donati M.B. Pathogenesis of thrombosis in patients with malignancy. Int. J. Hematol. 73:2001;137-144
12. Rickles F.R., Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb. Res. 102:2001;V215-V224
13. Lee A.Y. Cancer and thromboembolic disease: pathogenetic mechanisms. Cancer Treat. Rev. 28:2002;137-140
14. Caine G.J., Stonelake P.S., Lip G.Y., Kehoe S.T. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 4:2002;465-473
15. Kakkar V.V., Howe C.T., Nicolaides A.N., Renney J.T., Clarke M.B. Deep vein thrombosis of the leg. Is there a "high risk" group? Am. J. Surg. 120:1970;527-530
16. Lee A.Y., Levine M.N. The thrombophilic state induced by therapeutic agents in cancer patients. Semin. Thromb. Hemost. 25:1999;137-145
17. Agnelli G. Venous thromboembolism and cancer: a two-way clinical association. Thromb. Haemost. 79:1997;117-120
18. Minna JD, Bunn Jr PA. Paraneoplastic syndromes. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 3rd ed. Philadelphia: JB Lippincott; 1989. p. 1920-40.
19. Aderka D., Brown A., Zelikovski A., Pinkhas J. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer. 57:1986;1846-1849
20. Prandoni P., Lensing A.W., Büller H.R., et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N. Engl. J. Med. 327:1992;1128-1133
21. Silverstein R.L., Nachman R.L. Cancer and clotting-Trousseau's warning. N. Engl. J. Med. 327:1992;1163-1164
22. Nordström M., Lindblad B., Anderson H., Bergqvist D., Kjellström T. Deep venous thrombosis and occult malignancy: an epidemiological study. Br. Med. J. 308:1994;891-894
23. Goldberg R.J., Seneff M., Gore J.M., et al. Occult malignant neoplasm in patients with deep venous thrombosis. Arch. Int. Med. 147:1987;251-253
24. Sorensen H.T., Mellemkjaer L., Olsen J.H., Baron J.A. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 343:2000;1846-1850
25. Prandoni P. Prevention and treatment of deep-vein thrombosis in cancer patients. Vessels. 2:1996;31-34
26. Siragusa S., Cosmi B., Piovella F., Hirsh J., Ginsberg J.S. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am. J. Med. 100:1996;269-277
27. Bell W.R., Starksen N.F., Tong S., Porterfield J.K. Trousseau's syndrome. Devastating coagulopathy in the absence of heparin. Am. J. Med. 79:1985;423-430
28. Douketis J.D., Foster G.A., Crowther M.A., Prins M.H., Ginsberg J.S. Clinical risk factors and timing of recurrent thromboembolism during the initial 3 months of anticoagulant therapy. Arch. Int. Med. 160:2000;3431-3436
29. Alderman C.P., McClure A.F., Jersmann H.P., Scott S.D. Continuous subcutaneous heparin infusion for treatment of Trousseau's syndrome. Ann. Pharmacother. 29:1995;710-713
30. Prandoni P., Lensing A.W.A., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 100:2002;3484-34848
31. Hutten B.A., Prins M.H., Gent M., Ginsberg J., Tijssen J.G., Buller H.R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J. Clin. Oncol. 18:2000;3078-3083
32. Walsh-McMonagle D., Green D. Low-molecular-weight heparin in the management of Trousseau's syndrome. Cancer. 80:1997;649-655
33. Polareti G., Legnani C., Lee A., et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb. Haemost. 84:2000;805-810
34. Green K., Silverstein R.L. Hypercoagulability in cancer. Hematol. Oncol. Clin. North Am. 10:1996;499-530
35. Zhang Y., Deng Y., Luther T., et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J. Clin. Invest. 94:1994;1320-1327
36. Contrino J., Hair G., Kreutzer D.L., Rickles F.R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat. Med. 2:1996;209-215
37. Karpatkin S., Pearlstein E. Role of platelets in tumor cell metastases. Ann. Int. Med. 95:1981;636-641
38. Pearlstein E., Salk P.L., Yogeeswaran G., Karpatkin S. Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line. Proc. Natl. Acad. Sci. U.S.A. 77:1980;4336-4339
39. Bastida E., Ordinas A. Platelet contribution to the formation of metastatic foci: the role of cancer cell-induced platelet activation. Haemostasis. 18:1988;29-36
40. Cavanaugh P.G., Sloane B.G., Honn K.V. Role of the coagulation system in tumor-cell induced platelet aggregation and metastasis. Haemostasis. 18:1988;37-46
41. Warren B.A., Vales O. The adhesion of thromboplastic tumour emboli to vessel walls in vivo. Br. J. Exp. Pathol. 53:1972;301-313
42. Sallah S., Wan J.Y., Nguyen N.P., Hanrahan L.R., Sigounas G. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb. Haemost. 86:2001;828-833
43. Levi M., Ten Cate H. Disseminated intravascular coagulation. N. Engl. J. Med. 341:1999;586-592
44. Baglin T. Disseminated intravascular coagulation: diagnosis and treatment. Br. Med. J. 312:1996;683-687
45. Bick R.L. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin. Thromb. Hemost. 24:1998;3-15
46. Mombelli G., Roux A., Haeberli A., Straub P.W. Comparison of 125I-fibrinogen kinetics and fibrinopeptide A in patients with disseminated neoplasias. Blood. 60:1982;381-388
47. Yoda Y., Abe T. Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease. Thromb. Haemost. 46:1981;706-707
48. Rickles F.R., Edwards R.L., Barb C., Cronlund M. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth. Cancer. 5:1983;301-307
49. Rickles F.R., Edwards R.L. Activation of blood coagulation in cancer. Trousseau's syndrome revisited. Blood. 62:1983;14-31
50. Bick R.L. Coagulation abnormalities in malignancy: a review. Semin. Thromb. Hemost. 18:1992;353-372
51. Falanga A., Consonni R., Marchetti M., et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood. 92:1998;142-151
52. Sallah S., Gagnon G.A. Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel. Cancer Invest. 18:2000;191-196
53. Kies MS, Kwaan HC. Thromboembolism in cancer patients. In: Kwaan MC, Bowie EJW, editors. Thrombosis. Philadelphia: WB Saunders; 1982. p. 176-7.
54. Hajjar K.A. Fibrinolysis revisited: new insights into the pathobiology of cancer. Vessels. 2:1996;9-16
55. Juhan-Vague I., Valadier J., Alessi M.C., et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb. Haemost. 57:1987;67-72
56. Loreto M.F., De Matinis M., Corsi M.P., Modesti M., Ginaldi L. Coagulation and cancer: implication for diagnosis and management. Pathol. Oncol. Res. 64:2000;301-312
57. Black P.H. Shedding from normal and cancer-cell surfaces. N. Engl. J. Med. 303:1980;1415-1416
58. Black P.H. Shedding from the cell surface of normal and cancer cells. Adv. Cancer Res. 32:1980;75-199
59. Dvorak H.F., Quay S.C., Orenstein N.S., et al. Tumor shedding and coagulation. Science. 212:1981;923-924
60. Dvorak H.F., Van DeWater L., Bitzer A.M., et al. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res. 43(9):1983;4434-4442
61. Gale A., Gordon S. Update on tumor cell procoagulant factors. Acta Haematol. 106:2001;25-32
62. Hejna M., Raderer M., Zielinski C.C. Inhibition of metastases by anticoagulants. J. Natl. Cancer Inst. 91:1999;22-36
63. Gralnick H.R., Abrell E. Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukaemia. Br. J. Haematol. 24:1973;89-99
64. Garg S.K., Niemetz J. Tissue factor activity of normal and leukemic cells. Blood. 42:1973;729-735
65. Hudig D., Bajaj S.P. Tissue factor-like activity of the human monocytic tumor cell line U937. Thromb. Res. 27:1982;321-332
66. Kakkar A.K., DeRuvo N., Chinswangwatanakul V., Tebbutt J., Williamson R.C. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet. 346:1995;1004-1005
67. Morgan D., Edwards R.L., Rickels F.R. Monocyte procoagulant activity as a peripheral marker of clotting activation in cancer patients. Haemostasis. 18:1988;55-65
68. Semararo N. Different expression of procoagulant activity in macrophages associated with experimental and human tumors. Haemostasis. 18:1988;47-54
69. Edwards R.L., Rickles F.R. On the origin of leukocyte procoagulant activity. Thromb. Res. 13:1978;307-308
70. Edwards R.L., Rickles F.R., Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J. Lab. Clin. Med. 98:1981;917-928
71. Schwartz B.S., Edgington T.S. Immune complex-induced human monocyte procoagulant activity. I. A rapid unidirectional lymphocyte-instructed pathway. J. Exp. Med. 154:1981;892-896
72. Moake J.L. Hypercoagulable states. Adv. Int. Med. 35:1990;235-248
73. Lindahl A.K., Abildgaard U., Stokke G. Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb. Res. 59:1990;651-656
74. Korte W. Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures. Clin. Chem. Lab. Med. 38:2000;679-692
75. Gordon S.G., Franks J.J., Lewis B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb. Res. 6:1975;127-137
76. Gordon S.G., Franks J.J., Lewis B.J. Comparison of procoagulant activities in extracts of normal and malignant human tissue. J. Natl. Cancer Inst. 62:1979;773-776
77. Gordon S.G., Cross B.A. A factor X-activating cysteine protease from malignant tissue. J. Clin. Invest. 67:1981;1665-1671
78. Al-Mondhiry H., McGarvey V., Leitzel K. Interaction of human tumor cells with human platelets and the coagulation system. Thromb. Haemost. 50:1983;726-730
79. Falanga A., Gordon S.G. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry. 24:1985;5558-5565
80. Falanga A., Alessio M.G., Donati M.B., Barbui T. A new procoagulant in acute leukemia. Blood. 71(4):1988;870-875
81. Pineo G.F., Brain M.C., Gallus A.S., Hirsh J., Hatton M.W., Regoeczi E. Tumors, mucus production, and hypercoagulability. Ann. N.Y. Acad. Sci. 230:1974;262-270
82. Gasic G.J., Gasic T.B., Galanti N., Johnson T., Murphy S. Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease. Int. J. Cancer. 11(3):1973;704-718
83. Nachman R.L., Weksler B., Ferris B. Characterization of human platelet vascular permeability enhancing activity. J. Clin. Invest. 51:1972;549-556
84. Kessles C.M. Anticoagulation and thrombolytic therapy. Practical considerations. Chest. 95:1989;245S-256S
85. Broze G.J. Jr. Tissue factor pathway inhibitor. Thromb. Haemost. 74:1995;90-93
86. Honn K.V., Steinert B.W., Moin K., Onoda J.M., Taylor J.D., Sloane B.F. The role of platelet cyclooxygenase and lipoxygenase pathways in tumor cell induced platelet aggregation. Biochem. Biophys. Res. Commun. 145:1987;384-389
87. Clouse L.H., Comp P.C. The regulation of hemostasis: the protein C system. N. Engl. J. Med. 314:1986;1298-1304
88. Honegger H., Anderson N., Hewitt L.A., Tullis J.L. Antithrombin III profiles in malignancy. Thromb. Haemost. 46:1981;500-503
89. Rubin R.N., Kies M.S., Posch J.J. Measurement of antithrombin III in solid tumor patients with and without hepatic metastases. Thromb. Res. 18:1980;353-360
90. De Cicco M., Matovic M., Balestrieri L., et al. Antithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer patients. Thromb. Res. 78:1995;127-137
91. Rodeghiero F., Mannucci P.M., Vigano S., et al. Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood. 63:1984;965-969
92. Bauer K.A., Ten Cate H., Barzegar S., Spriggs D.R., Sherman M.L., Rosenberg R.D. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood. 74:1989;165-172
93. Whitehead R.P., Fleming T., Macdonald J.S., et al. A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study. J. Biol. Response Mod. 9:1990;588-591
94. Rella C., Coviello M., Giotta F., et al. A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res. Treat. 40:1996;151-159
95. Rogers J.S., Murgo A.J., Fontana J.A., Raich P.C. Chemotherapy for breast cancer decreases plasma protein C and protein S. J. Clin. Oncol. 6:1988;276-281
96. Feffer S.E., Carmosino L.S., Fox R.L. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer. 63:1989;1303-1307
97. Kuzel T., Esparaz B., Green D., Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer. 65:1990;885-889
98. Lipton A., Harvey H.A., Hamilton R.W. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat. Rep. 68:1984;887-888
99. Levine M.N., Gent M., Hirsh J., et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N. Engl. J. Med. 318:1988;404-407
100. Saphner T., Tormey D.C., Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J. Clin. Oncol. 9:1991;286-294
101. Deshmukh N., Tripathi S.P. Thrombosis of tibial arteries in a patients receiving tamoxifen therapy. Cancer. 76:1995;1006-1008
102. Pritchard K.I., Paterson A.G., Paul N.A., Zee B., Fine S., Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J. Clin. Oncol. 14:1996;2731-2737
103. Rivkin S.E., Green S., Metch B., Cruz A.B. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J. Clin. Oncol. 12:1994;2078-2085
104. Fisher B., Redmond C., Legault-Poisson S. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J. Clin. Oncol. 8:1990;1005-1018
105. Bleyer W.A., Breckenridge R.T. Studies on the detection of adverse drug reactions in the newborn II. The effect of prenatal aspirin on newborn hemostasis. JAMA. 213:1970;2049-2053
106. Stirling Y., Woolf L., North W.R., Seghatchian M.J., Meade T.W. Haemostasis in normal pregnancy. Thromb. Haemost. 52:1984;176-182
107. Auger M.J., Mackie M.J. Effects of tamoxifen on blood coagulation. Cancer. 61:1988;1316-1319
108. Bertina R.M., Koeleman B.P., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein. Nature. 369:1994;64-67
109. Rosendaal F.R., Koster T., Vandenbroucke J.P., Reitsma P.H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 85:1995;1504-1508
110. Ridker P.M., Hennekens C.H., Lindpaintner K., Stampfer M.J., Eisenberg P.R., Miletich J.P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction. N. Engl. J. Med. 332:1995;912-917
111. Weitz I.C., Israel V.K., Liebman H.A. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer. 79:1997;2024-2027
112. Walsh J.J., Bonnar J., Wright F.W. A study of pulmonary embolism and deep leg vein thrombosis after major gynaecological surgery using labeled fibrinogen-phlebography and lung scanning. J. Obstet. Gynaecol. Br. Commonw. 81:1974;311-316
113. Sue-Ling H.M., Johnston D., McMahon M.J., Philips P.R., Davies J.A. Pre-operative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet. 1:1986;1173-1176
114. Levine M. Cancer Patients. In: Goldhaber SZ, editors. Prevention of venous thromboembolism. New York: Marcel Dekker; 1993. p. 463-83.
115. Huber O., Bounameaux H., Borst F., Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch. Surg. 127:1992;310-313
116. Falanga A., Ofosu F.A., Cortelazzo S., et al. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br. J. Haematol. 85:1993;745-750
117. Schreiber D.P., Kapp D.S. Axillary-subclavian vein thrombosis following combination chemotherapy and radiation therapy in lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 12:1986;391-395
118. Wilson C.B., Lambert H.E., Scott R.D. Subclavian and axillary vein thrombosis following radiotherapy for carcinoma of the breast. Clin. Radiol. 38:1987;95-99
119. Hallahan D., Chen A.Y., Teng M., Cmelac A.J. Drug-radiation interactions in tumor blood vessels. Oncology (Huntingt.). 13:1999;71-77
120. Bona R. Thrombotic complications of central venous catheters in cancer patients. Semin. Thromb. Hemost. 25:1999;147-155
121. Lokich J.J., Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer. 52:1983;1586-1589
122. Bern M.M., Lokich J.J., Wallach S.R. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann. Int. Med. 15(112):1990;423-428
123. Monreal M., Lafoz E., Ruiz J., Valls R., Alastrue A. Upper-extremity deep venous thrombosis and pulmonary embolism. A prospective study. Chest. 99:1991;280-283
124. De Cicco M., Matovic M., Balestreri L., et al. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb. Res. 86:1997;101-113